In conclusion, PARP inhibitor combined with platinum-based chemotherapy was proved as the optimal treatment for patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/2 pathogenic variants in terms of efficacy outcomes, namely ORR, PFS, and OS. This evidence concerns the gene BRCA1 and breast carcinoma.